Unknown

Dataset Information

0

Extracellular Matrix-Dependent Generation of Integration- and Xeno-Free iPS Cells Using a Modified mRNA Transfection Method.


ABSTRACT: Human induced pluripotent stem cells (iPS cells) hold great promise in the field of regenerative medicine, especially immune-compatible cell therapy. The most important safety-related issues that must be resolved before the clinical use of iPS cells include the generation of "footprint-free" and "xeno-free" iPS cells. In this study, we sought to examine whether an extracellular matrix- (ECM-) based xeno-free culture system that we recently established could be used together with a microRNA-enhanced mRNA reprogramming method for the generation of clinically safe iPS cells. The notable features of this method are the use of a xeno-free/feeder-free culture system for the generation and expansion of iPS cells rather than the conventional labor-intensive culture systems using human feeder cells or human feeder-conditioned medium and the enhancement of mRNA-mediated reprogramming via the delivery of microRNAs. Strikingly, we observed the early appearance of iPS cell colonies (~11 days), substantial reprogramming efficiency (~0.2-0.3%), and a high percentage of ESC-like colonies among the total colonies (~87.5%), indicating enhanced kinetics and reprogramming efficiency. Therefore, the combined method established in this study provides a valuable platform for the generation and expansion of clinically safe (i.e., integration- and xeno-free) iPS cells, facilitating immune-matched cell therapy in the near future.

SUBMITTER: Lee KI 

PROVIDER: S-EPMC4737460 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Extracellular Matrix-Dependent Generation of Integration- and Xeno-Free iPS Cells Using a Modified mRNA Transfection Method.

Lee Kang-In KI   Lee Seo-Young SY   Hwang Dong-Youn DY  

Stem cells international 20160112


Human induced pluripotent stem cells (iPS cells) hold great promise in the field of regenerative medicine, especially immune-compatible cell therapy. The most important safety-related issues that must be resolved before the clinical use of iPS cells include the generation of "footprint-free" and "xeno-free" iPS cells. In this study, we sought to examine whether an extracellular matrix- (ECM-) based xeno-free culture system that we recently established could be used together with a microRNA-enhan  ...[more]

Similar Datasets

2016-04-21 | GSE68035 | GEO
| S-EPMC7492356 | biostudies-literature
| S-EPMC4073818 | biostudies-literature
| S-EPMC3187830 | biostudies-literature
| S-EPMC6720767 | biostudies-literature
| S-EPMC3809786 | biostudies-other
| S-EPMC5609845 | biostudies-literature
2015-09-14 | GSE61403 | GEO
| S-EPMC3458059 | biostudies-literature
2015-09-14 | E-GEOD-61403 | biostudies-arrayexpress